188.30DKK-5.09%Mkt Cap: 14.40B DKKP/E: 12.47Last update: 2026-05-13
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human u…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)12.47
P/E (Forward)17.24
PEG1.87
P/B1.14
P/S2.42
EV/EBITDA8.75
EV/Revenue2.06
EPS (TTM)15.10
EPS (Forward)10.92
Cash Flow & Leverage
FCF Yield-3.51%
FCF Margin-8.50%
Operating CF2.72B DKK
CapEx (TTM)1.36B DKK
Net Debt/EBITDA-1.54
Net Debt-2.15B DKK
Technical
SMA 50190.46 (-1.1%)
SMA 200205.50 (-8.4%)
Beta0.95
S&P 52W Chg24.23%
Avg Vol (30d)254.50K
Avg Vol (10d)312.61K
Technical Indicators
RSI (14)46.1
MACD-0.1285
MACD Signal-0.5661
MACD Hist.+0.4376
BB Upper200.31 DKK
BB Middle190.69 DKK
BB Lower181.08 DKK
BB Width10.08%
ATR (14)5.236 DKK
Vol Ratio (20d)3.76x
52W Range
153.4538% of range244.80
52W High244.80 DKK
52W Low153.45 DKK
Profitability
Gross Margin48.83%
EBITDA Margin23.50%
Profit Margin22.03%
Oper. Margin-0.66%
ROE10.69%
ROA9.20%
Revenue Growth-21.40%
Earnings Growth-92.60%
Balance Sheet
Debt/Equity0.01
Current Ratio6.47
Quick Ratio3.50
Book Value/Sh164.47 DKK
Cash/Share29.97 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.76.49M
Float76.35M
Insiders0.05%
Institutions31.14%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)271.67 DKK
Target Range260.00 DKK – 280.00 DKK
# Analysts3
Company
Market Cap14.40B DKK
Enterprise Value12.25B DKK
Revenue (TTM)5.96B DKK
Gross Profit3.05B DKK
Net Income (TTM)1.38B DKK
Revenue/Share75.42 DKK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.9K
Last Price188.30 DKK
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—